NZ Expands Access to Brentuximab for Blood Cancer Patients from 2026

Associate Health Minister David Seymour and Health Minister Simeon Brown support Pharmac’s proposal to expand access to brentuximab as a first-line treatment for systemic anaplastic large cell lymphoma, aiming to improve survival rates and quality of life. The government has increased Pharmac’s budget significantly, enabling funding for 43 new cancer treatments and expanding stem cell transplant services to reduce wait times and help more patients receive timely care. If approved, the proposal will take effect on April 1, 2026, reflecting the government’s commitment to enhancing cancer treatment access and outcomes in New Zealand.